SimBioSys is delivering on the promise of precision cancer care by combining the power of science and software into a biophysical simulation platform.
Champaign + Chicago
Joined November 2017
- Tweets285
- Following345
- Followers173
- Likes330
SimBioSys retweeted
🎙 Listen to @jerskillington, CEO of @PoolbegPharma and Tushar Pandey, CEO and Co-founder of @SimBioSys, as they discuss the growing role of #AI in drug development on the latest episode of #OptimumPerspectives!
Stream the full episode here: Optimum Perspectives Podcast – Optimum Strategic Communications (optimumcomms.com) and don't forget to subscribe on your favourite podcast platform so you never miss the latest updates from the #LifeScience community brought to you by #OptimumStrategicCommunications!
SimBioSys retweeted
@SimBioSys CEO Tushar Pandey was interviewed in a recent episode of the CRPN Central Podcast. It's always great to hear from EnterpriseWorks tenants: listen to this podcast today at drfoxt.podbean.com/e/breast-….
SimBioSys retweeted
Check out this #breastcancer article from #ASCO23
The Early-stage Triple Negative Breast Cancer Journey: Beginning, End and Everything in Between. ascopubs.org/doi/full/10.120…
@JCO_ASCO @ONealCancerUAB
@UABDeptMed
@MoffittNews
@UIowaCancer
SimBioSys retweeted
Identifying and Mitigating Health Disparities in Breast Cancer Care at Miami Breast Cancer Conference @OtisBrawley @DrWinkfield @raalbany @gotoPER #healthdisparities
SimBioSys retweeted
Thank you @GoHealio for sharing my story #WomenInMedicine @WIMSummit @YaleMed @YaleCancer healio.com/news/hematology-o…
SimBioSys retweeted
Thank you @lab_kok for highlighting #ILC! yes we are "The unseen" but we are determined to change that #SABCS22 #EndCancer @OncoAlert – at San Antonio, TX
Research into #lobular #breastcancer was featured in the Year in Review wrap-up on the last day of #SABCS2022. Great to see #ILC research happening and to see active calls for further elevation. #lobmob #oncoalert @LobularBCA @LobularBCUK @LobularIreland #RepresentationMatters
SimBioSys retweeted
Please vote for this amazing team!
#bcsm @DFCI_BreastOnc
@stolaney1 @DrHBurstein @AnnPartridgeMD @nlinmd @elmayermd - our work looking at racial differences in the immune response to breast cancer is a finalist for the BRIght futures prize. Can we count on your vote? (And spread the word😊)
SimBioSys retweeted
When you have this kind of results, hard to do whatever you want. No consensus. Need to follow the original regimen for now. Just my two cents. #ESMO22 – at Houston, TX
SimBioSys retweeted
Thank you so much for sharing our piece, @DrSGraff! I like to believe that, in 2030, we’ll look back and see a decade of tremendous advancements in drug development & biomarker discovery, finally allowing for right-sizing in the (neo) adjuvant treatment of patients with TNBC
Next, PubMed put this great look forward into the future of immunotherapy & triple negative breast cancer from @PTarantinoMD and a list of brilliant co-authors in my hands. (Sorry—missed it in Feb) 2/
nature.com/articles/s41523-0… #bcsm
SimBioSys retweeted
The University of Chicago is searching for an academic breast medical oncologist. Please visit: apply.interfolio.com/89586 to apply.
EOE/Vet/Disability.
We have a fun and collaborative group with so many research opportunities! Come join our group. #BCSM
SimBioSys retweeted
Out on @CCR_AACR the FDA Approval Summary for neoadjuvant pembro in TNBC. A huge leap forward in the treatment of this aggressive disease, but also a step back in treatment tailoring. We’re clearly overtreating some patients: urgent need for biomarkers.
aacrjournals.org/clincancerr…
SimBioSys retweeted
Presented at #ESMO VP6, IMpassion050 is now published on JCO. The addition of atezo to neoadjuvant ddAC-T+HP doesn’t increase pCR rates in HER2+ EBC, neither in ITT (left) nor PD-L1+ (right). Significant increase in toxicity with atezo, including 5 deaths.
ascopubs.org/doi/abs/10.1200…
SimBioSys retweeted
The University of Chicago is searching for an academic breast medical oncologist. Please visit: apply.interfolio.com/89586.
EOE/Vet/Disability.
We are very interested in individuals with an interest in clinical/translational/disparities research.
SimBioSys retweeted
#ASCO22 is only 2 weeks away! Below are my Top 10 abstracts I'm looking forward to in #bcsm across early & metastatic settings.
I've also attached the "why" - what is intriguing me about these particular abstracts or why they are important IMO.
@SarahCannonDocs @OncoAlert
SimBioSys retweeted
Expectations for #ESMOBreast22 were high, but they were ultimately widely exceeded! Great in-person and virtual attendance, important new data & brilliant educationals made of this congress a terrific experience.
Here’s my #top10 (+ bonus) Take Home Messages from #ESMOBreast22
SimBioSys retweeted
The field of breast cancer is changing rapidly- w/many new agents emerging quickly. @DFCI_BreastOnc is putting together guidelines to help physicians w/how to utilize new agents in clinic. Here are our first 2 on adj abema and preop pembro. More to come!
# bcsm @DanaFarber
We are pleased to share recommended guidelines developed by our @DFCI_BreastOnc faculty on how physicians can best utilize preoperative pembrolizumab and adjuvant abemaciclib for the treatment of early-stage breast cancer
physicianresources.dana-farb… #bcsm
SimBioSys retweeted
Is there a #TNBC subset that is actually endocrine sensitive? #LAR
~10%
But modest endocrine effect with the AR inhibitors we have seen so far
#AACR @DrLisaCarey
SimBioSys retweeted
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. DESTINY-03 breast cancer data is now published in @NEJM. An important milestone and practice-changing. nejm.org/doi/full/10.1056/NE… #bcsm #oncoalert
SimBioSys retweeted
OS improved by 3%, distant recurrence improved by 5%.
A new bar that even for those without pCR we are hitting survival of almost 90%...this is a big step forward in personalized #bcsm treatment.
@OncoAlert @SarahCannonDocs – at Nassau Bay, TX
SimBioSys retweeted
Neoadj Nivolumab + Chemo now @FDAOncology approved for NSCLC.
#CM816: Ph3, N= 358, Neoadjuvant, Nivo + Chemo Vs Chemo alone, resectable IB-IIIA NSCLC
- pCR of 24% vs 2% with Nivo
- improved EFS
@OncoAlert #LCSM @ASCO #MedTwitter #OncEd
